SCHEMBL17072292

SCHEMBL17072292

O=C(Nc1ccc(-n2ncc3cc(NC(=O)c4ccc(N5CCC(F)CC5)cc4)ccc32)cc1)c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
CRACR2A Q9BSW2 2/20 0.48
MAOB P27338 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 2/20 0.46
GAA P10253 1/20 0.46
SLC2A1 P11166 2/20 0.46
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
MAPK8 P45983 3/20 0.44
MAPK10 P53779 3/20 0.44
MAPK13 O15264 2/20 0.44
MAPK12 P53778 2/20 0.44
MAPK11 Q15759 2/20 0.44
MAPK14 Q16539 2/20 0.44
TP53 P04637 3/20 0.44
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1666463 0.93 MAPT (0.52) MAPTCRACR2AMAOBSMN1; SMN2NPC1
SCHEMBL13964696 0.92 MAPT (0.57) MAPTCRACR2AMAOBSMN1; SMN2NPC1
SCHEMBL1666461 0.87 MAPT (0.50) MAPTCRACR2AMAOBSMN1; SMN2NPC1
SCHEMBL1665085 0.85 SMO (0.53) MAPTMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL1665372 0.84 MAOB (0.44) MAPTCRACR2AMAOBSMN1; SMN2NPC1
SCHEMBL6126511 0.84 MAOB (0.46) MAPTMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL1665077 0.84 MAOB (0.43) MAPTCRACR2AMAOBSMN1; SMN2NPC1
SCHEMBL1664913 0.84 MAPT (0.59) MAPTMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL1663344 0.84 MAOB (0.56) MAPTMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL13964704 0.84 MAPT (0.55) MAPTMAOBSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MAPT 4411/4885CRACR2A 324/4885MAOB 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.